Patient Selection and Procedural Considerations for Coronary Orbital Atherectomy System

Yohei Sotomi,¹ Richard A Shlofmitz,² Antonio Colombo,³ Patrick W Serruys⁴ and Yoshinobu Onuma⁵

1. Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2. St Francis Hospital, The Heart Center, Roslyn, New York, USA;

3. EMO-GVM Centro Cuore Columbus, Milan, Italy; 4. International Centre for Circulatory Health, NHLI, Imperial College London, London, UK;

5. ThoraxCenter, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract

Despite advances in technology, percutaneous coronary intervention (PCI) of severely calcified coronary lesions remains challenging. Rotational atherectomy is one of the current therapeutic options to manage calcified lesions, but has a limited role in facilitating the dilation or stenting of lesions that cannot be crossed or expanded with other PCI techniques due to unfavourable clinical outcome in long-term follow-up. However the results of orbital atherectomy presented in the ORBIT I and ORBIT II trials were encouraging. In addition to these encouraging data, necessity for sufficient lesion preparation before implantation of bioresorbable scaffolds lead to resurgence in the use of atherectomy. This article summarises currently available publications on orbital atherectomy (Cardiovascular Systems Inc.) and compares them with rotational atherectomy.

Keywords

Orbital atherectomy system, percutaneous coronary intervention, severely calcified lesion

Disclosure: YS is a consultant for GOODMAN and has received a grant from Fukuda Memorial Foundation for Medical Research and SUNRISE lab. RAS has received speaking honoraria from Cardiovascular Systems Inc. and St Jude Medical. PWS and YO are members of Advisory Board of Abbott Vascular. AC has no conflicts of interest to declare.

Acknowledgement(s): The authors thank Robert Kohler from Cardiovascular Systems Inc. for editing and critical review of this manuscript.

Received: 31 December 2015 **Accepted:** 10 March 2016 **Citation:** *Interventional Cardiology Review*, 2016; **11**(1):33–8 DOI: 10.15420/icr.2015.19:2

Correspondence: Yoshinobu Onuma, ThoraxCenter, Ba-583's Gravendijkwal 230 3015 CE Rotterdam, The Netherlands. E: yoshinobuonuma@gmail.com

From the early days of percutaneous coronary intervention (PCI) it became apparent that the presence of severe coronary calcification was a predictor of worse clinical outcomes. In the era of plain old balloon angioplasty, severe coronary calcification was associated with an increased risk of coronary dissection and procedural failure, while in the bare-metal stent era, it was associated with a higher incidence of in-stent restenosis and target lesions revascularisations (TLRs).^{1,2} The advent of drug-eluting stents (DES) changed the landscape of coronary intervention through the reduced risk of restenosis and TLR, thereby allowing the interventional treatment of complex lesions and high-risk patients. However, a recent patient-level pooled analysis from seven contemporary stent trials revealed that patients with severely calcified lesions still have worse clinical outcomes compared with those without severe coronary calcification.³ Patients with severe lesion calcification were less likely to have undergone complete revascularisation, resulting in a higher residual Syntax score, which is a powerful determinant of prognosis.⁴

Although rotational atherectomy was expected to be one of the solutions, the prospective, randomised ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial did not demonstrate any better clinical outcomes.^{5,6} The latest ACCF/AHA/SCAI and ESC/EACTS PCI guidelines and European expert consensus on rotational atherectomy state that rotational atherectomy has a limited role in facilitating the dilation or stenting of lesions that cannot be crossed or expanded with PCI.^{7–12}

Rotational atherectomy should not be performed routinely for *de novo* lesions or in-stent restenosis.¹³

Recently, a newly developed atherectomy device, a Diamondback 360[®] Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems Inc.) has been approved by the US Food and Drug Administration (FDA) based on the results of the Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions (ORBIT) II trial¹⁴ and is a new treatment option for severely calcified coronary lesions. The purpose of this review is to provide insights for procedural considerations and patient selection from the currently available publications assessing the OAS.

Diamondback 360[®] Coronary Orbital Atherectomy System

The Diamondback 360[®] Coronary OAS is the device to facilitate stent delivery in patients who are acceptable candidates for PCI due to *de novo*, severely calcified coronary artery lesions (see *Figure 1*). The Diamondback 360[®] Coronary OAS is the device to facilitate stent delivery in patients who are acceptable candidates for PCI due to *de novo*, severely calcified coronary artery lesions. In October 2013, Cardiovascular Systems Inc. received FDA approval for the use of the Diamondback Coronary OAS in the US, whereas it has yet to receive CE Mark in Europe. Only one size of crown (1.25 mm) is required for the coronary OAS. ViperWire Advance[®] coronary guide wire (335 cm)

Figure 1: Diamondback 360® Coronary Orbital Atherectomy System

(A) Diamondback 360® Coronary Orbital Atherectomy System. (B) 1.25 mm coronary classic crown. (C) Orbital motion. (D) Electron micrograph of the crown. (Reprinted with permission from Copyright Cardiovascular Systems Inc.) IV = intravenous; OAS = orbital atherectomy system.

Figure 2: Maximum Lumen Diameters after Orbital Atherectomy with 1.25 mm Classic Crown

The graph shows the relationship between number of passes, travel rate, rotational speed and lumen diameter in a carbon block model. A pass is defined as once out and back across the lesion. Orbit data presented are based on a 6 cm pass distance. The table indicates maximum lumen diameter after 5 minutes of orbital atherectomy. A travel rate of 10 mm per second with 20 passes through a 6 cm lesion is approximately 5 minutes of treatment time. A travel rate of 1 mm per second with two passes through a 6 cm lesion is also approximately 5 minutes of treatment time. Actual clinical results may vary. SD = standard deviation. ((c) 2016; reprinted with permission from Copyright Cardiovascular Systems Inc.)

is to be used exclusively with the Diamondback 360® Coronary OAS to enable optimal orbital path and efficient differential sanding.

The Diamondback 360® Coronary OAS uses a differential sanding mechanism of action to reduce plaque while potentially minimising damage to the medial layer of the vessel. Softer tissue flexes away from the crown while fibrotic tissue or arterial calcium is engaged and treated facilitating stent deployment. A drive shaft with an eccentrically mounted diamond-coated crown provides proximal and distal sanding to reduce occlusive material and restore luminal patency.¹⁵ The crown's orbital diameter expands radially via centrifugal force according to the following formula: $F = mv^2/R$ (F = centrifugal force; m = mass of the crown; v = velocity [device rotational speed]; R = radius of rotation) (see Figure 1). Operators can control the speed of rotation with the knowledge that a higher speed will create a larger sanding diameter by increasing lateral pressure (see Figure 2). Based on carbon block testing, the average particle size created by OAS is 2.04 μ m; 98.3 % of particles are smaller than red blood cell diameter; and 99.2 % of particles are smaller capillary diameter (see Figure 3). In the US, a physician training and certification programme based on physician atherectomy experience is required to use OAS. All physicians must complete an online training module and complete six clinical proctored cases. Based on their experience level they may also need to attend a preceptorship course.

Procedural Consideration for Coronary Orbital Atherectomy System in Comparison with Rotational Atherectomy

Basic procedural consideration for orbital atherectomy can be similar to that of rotational atherectomy.^{12,16,17} Differential aspects between orbital atherectomy and rotational atherectomy are summarised in Table 1.

One advantage of the Diamondback 360 Coronary OAS is the ease of use. The electric handle allows the user to simply plug in the device, and the only portion of the Diamondback 360 Coronary OAS that is not in the operating field is the saline infusion pump.¹⁸ The orbital path of the device around the periphery of the lumen allows the crown to attack the plaque, in contrast with the burr of a rotational device, which remains in one place. In both rotational atherectomy and orbital atherectomy, a healthy, compliant tissue should flex away, whereas fibrotic calcific lesions would generate an opposing force, allowing differential cutting and differential sanding, respectively. The OAS uses a principle of off-axis centrifugal force, with the orbital motion diameter being proportional to the applied speed. Operators can adjust the ablation diameter by controlling the rotational speed without changing the device crown size (see Figure 2). The unique crown shape and diamond coating enable ablation of severely calcified lesions forward and backward, minimising burr entrapment rates. The device allows constant blood and saline flow and particulate flushing during orbit, which facilitates cooling, minimising the potential for ischemia and thermal trauma, which can be a potential cause of restenosis. In comparison, rotational atherectomy uses a concentric burr that does not allow blood and micro-debris to flow past the burr. The average particle size created by rotational atherectomy is 5–10 μ m,¹⁹ while the average particle size by orbital atherectomy is approximately 2 μ m,¹⁵ resulting in its lower incidence of slow flow or no reflow than that of rotational atherectomy.

A case example treated with the OAS is demonstrated in Figure 4. OCT images pre- and post-orbital atherectomy show the appearance of ablated plaque. The 'guidewire bias' (intraluminal [eccentric] position

Table 1: Differential Aspects of the Orbital Atherectomy from the Rotational Atherectomy

	Rotational Atherectomy	Orbital Atherectomy
Device	Rotablator™ Rotational Atherectomy System	Diamondback 360® Coronary Orbital Atherectomy System
Manufacturer	Boston Scientific Scimed, Maple Grove, Minnesota	Cardiovascular Systems, Inc., St. Paul, Minnesota
Rotation	Rotational motion	Orbital motion
Guidewire	RotaWire™ (ROTAWIRE Floppy, ROTAWIRE Extra Support)	ViperWire Advance® Guide Wire
Lubricant	Rotaglide™	ViperSlide®
Concept	Differential cutting	Differential sanding
Device size selection	1.25, 1.50, 1.75, 2.00, 2.15, 2.25, 2.38, and 2.50 mm (Burr) Plaque modification with small burrs (1.25 mm to 1.5 mm) as initial strategy is default position. A step-up approach is encouraged to limit debris size and complications. ¹²	1.25 mm (Crown)
Ablation speed	Plaque modification usually achieved at low speeds (135,000 to 180,000 rpm) to reduce risk of complications ¹²	Low speed (80,000 rpm) or high speed (120,000 rpm). Initial treatment for each lesion must start at low speed ³⁷
Adjustable ablation diameter	No (necessary to change the burr size)	Yes (just control the rotational speed)
Ability to ablate forward and backward	No	Yes (minimising burr entrapment rates)
Continuous blood flow during ablation	No	Yes (minimising the potential for ischaemia and thermal trauma)
Temporary pacemaker	Smaller burrs at lower speeds have led to lower incidence of transient heart block Many operators use atropine to treat, avoiding any complications of temporary pacemaker placement ¹²	A temporary pacing lead may be necessary when treating lesions in the right coronary and circumflex arteries due to the possible occurrence of electrophysiological alternations. ³⁷ However, in a real-world setting, only 3.5 % of the patients undergoing orbital atherectomy had a temporary pacemaker placed with 0.9 % requiring activation of pacing ³⁸
Flush	Rotablation cocktail with verapamil, nitrates and heparin in saline recommended ¹²	No specific recommendation
Particle size	5–10 micron ¹⁹	2 micron ¹⁵
Incidence of slow flow/no-reflow	6–15 % ^{25,26}	0.9 % ¹⁴
Coronary perforation	0.4–2.5 % ^{5,6,27–30}	1.8 % ¹⁴

of the supporting wire) seems important for the effective ablation not only during rotational atherectomy but also during orbital atherectomy. In addition, imaging evaluation by intravascular ultrasound (IVUS) or OCT after the orbital atherectomy might be recommended for sufficient lesion preparation,^{20,21} since the ablation diameter largely varies depending on the run time, number of passes and rotational speed (see Figure 2). Without imaging assessment, the efficacy of orbital atherectomy could highly depend on the experience of operators.

Clinical Evaluation for Coronary Orbital Atherectomy System

We conducted a literature search to identify all published coronary OAS studies and Summarized their results in Table 2. Two landmark trials (ORBIT I and ORBIT II) from India and the US have demonstrated the clinical safety and efficacy of the OAS, resulting in the approval by FDA in 2013. No clinical data in a direct comparison study between orbital atherectomy and rotational atherectomy is available so far.

The first-in-man assessment of the coronary OAS to treat *de novo* calcified coronary lesions was performed in the ORBIT I clinical trial.²² Fifty patients with *de novo* calcified coronary lesions were enrolled in this non-randomised, multi-centre trial in India. Procedural success, defined as ≤ 20 % residual stenosis after stent placement, was achieved in 94 % of patients. There was no incidence of slow flow or distal embolisation. In contrast to previous

Figure 3: Particulate Size Distribution

The graph shows the particulate size distribution after orbital atherectomy from a carbon block model. Ninety-nine per cent of particulate caused by the Diamondback 360® orbital atherectomy system is small enough to fit through the capillaries (data on file). © 2016; reprinted with permission from Cardiovascular Systems Inc.)

PCI trials with rotational atherectomy, ORBIT I reported low rates of major adverse cardiac events (MACE) (6 % at 30 days and 8 % at 6 months).²² Long-term follow-up was collected on a single-centre subset of ORBIT I subjects enrolled at CIMS Hospital, India (n=33). Of the 33 subjects, the observed MACE rate at 2 years was 15 % (5/33), 3 years was 18 % (6/33) and 5 years 21 % (7/33).^{23,24}

The ORBIT II trial was a prospective, single-arm multicentre, non-blinded clinical trial that enrolled 443 consecutive patients with severely calcified

Table 2: Trials Assessing Orbital Atherectomy System

Study Title	Study Design	Patient Number	Primary Outcome	Secondary Outcome	Results	Reference(s)
ORBIT I	A prospective, single-arm, multi-centre study	50	Device performance, procedural success, TLR and overall MACE rates at 6 months	NS	Device success 98 %, procedural success 94 %, TLR 2 %, MACE 8 %	20,23,24
ORBIT II	A prospective, single-arm, multi-centre study	443	Procedural success and 30-day MACE	Angiographic success, severe angiographic complications, 12-month MACE	Procedural success 88.9 %, 30-day MACE 10.4 %; 12-month MACE 16.4 %; angiographic success 91.4 %; severe angiographic complications 7.2 %	14,39
Kini et al.	A retrospective, double-arm, single-centre, OCT-imaging study	20 (10 OA versus 10 RA)	NS	NS	Deeper dissections post-OAS than post-RA (1.14 versus 0.82 mm; P=0.048). Lower per cent of stent strut malapposition post-OAS than post-RA (4.36 versus 8.02 %; P=0.038).	31
Ruisi et al.	A single-arm, single-centre study	50 (all transradial approach)	NS	NS	30-day MACE 0 %; radial artery occlusion rate 6 %	40
Dib et al.	A prospective, single-arm, multi-centre study	15	Change in coronary flow reserve	Presence/absence of MACE during hospitalisation	Still ongoing/not published	41
COAST	A prospective, single-arm, multi-centre study	100	30-day MACE	Procedural success	Still ongoing/not published	42

MACE = major adverse cardiac events; NS = not specified; OA(S) = orbital atherectomy (system); OCT = optical coherence tomography; TLR = target lesion revascularisation; RA = rotational atherectomy.

coronary lesions at 49 US sites from 25 May 2010 to 26 November 2012.¹⁴ The Diamondback 360® Coronary OAS was used to prepare severely calcified lesions for stent placement. The primary safety endpoint was 89.6 % freedom from 30-day MACE compared with the performance goal of 83 %. The primary efficacy endpoint (residual stenosis <50 % post-stent without in-hospital MACE) was 88.9 % compared with the performance goal of 82 %. Stent delivery was performed successfully in 97.7 % of cases with <50 % residual stenosis in 98.6 % of subjects. Low rates of in-hospital Q-wave MI (0.7 %), cardiac death (0.2 %) and target vessel revascularisation (0.7 %) were reported. The incidence of slow flow or no reflow in the rotational atherectomy has been reported to be 6 % to 15 %, ^{25,26} whereas in the ORBIT II trial the rate of persistent slow flow/no reflow for orbital atherectomy were notably very low, occurring in 0.9 % of patients.¹⁴ Perforations occurred in 1.8 % of patients compared with 0.4 % to 2.5 % in the several rotational atherectomy studies reporting on this complication.^{5,6,27-30} The ORBIT II perforation rate is within the previously reported range. The ORBIT II trial met both the primary safety and efficacy endpoints by significant margins and not only helped facilitate stent delivery, but also improved both acute and 30-day clinical outcomes compared with historical controls in this difficult-to-treat patient population.

The comparison study by Kini et al. assessed the mechanistic difference of impact by rotational atherectomy and orbital atherectomy with OCT.³¹ Although the number of the study population was limited, precise imaging analyses revealed that tissue modification with deep dissections in around a third of lesions after rotational atherectomy and orbital atherectomy; however, post-orbital atherectomy dissections were significantly deeper than post-rotational atherectomy (1.14 versus 0.82 mm; P=0.048). Stents after orbital atherectomy were associated with a significantly lower per cent of stent strut malapposition than those after rotational atherectomy (4.36 versus 8.02 %; P=0.038).

In comparison with rotational atherectomy, more significant modification of heavily calcified plaques by the orbital atherectomy led to better stent expansion and apposition, which might result in a lower MACE rate in the previous two landmark studies.

Patient Selection for Coronary Orbital Atherectomy System

The indication of rotational atherectomy according to the expert consensus and guidelines is for calcified lesions, which, in the absence of plaque modification, confer an increased likelihood of procedural failure, stent under expansion, restenosis and major complications.^{9,10,12,32} Although routine use of rotational atherectomy did not improve outcomes after DES implantation,^{5,6} such a device might technically be required in cases of tight and calcified lesions, to allow subsequent passage of balloons and stents. In most cases, the simple passage of a single burr is sufficient to smoothen the vessel lumen, or to disrupt the continuity of intravascular calcium rings, to enable subsequent balloon dilatation and stent implantation.

Orbital atherectomy is indicated for severe calcium of coronary *de novo* lesions. In addition, since the OAS could simplify the procedure with its small crown size and adjustable ablation diameter with the rotational speed control, the procedural simplification could extend the clinical application of the orbital atherectomy device to several potential situations as follows.

Multi-vessel Disease With Severely Calcified Lesions

Patients with multi-vessel disease and severely calcified lesions are less likely to have undergone complete revascularisation,³ resulting in a higher residual Syntax score which is a powerful determinant of prognosis.⁴ Both rotational atherectomy and orbital atherectomy can facilitate the device delivery and complete revascularisation, which could help achieve a lower residual Syntax score. So far there is

not robust evidence that the decalcification strategy with rotational atherectomy and extensive metallic stent implantation could improve clinical outcomes.^{5,33} This should be investigated and proved with use of orbital atherectomy.

Lesion Preparation for Implantation of Bioresorbable Scaffolds

Bioresorbable scaffolds appear to overcome the limitations of the permanent metallic stents, but technically require more extensive lesion preparation, especially in calcified lesions due to its limited mechanical strength. There is resurgence in the use of atherectomy for the purpose of optimal lesion preparation among patients undergoing implantation of bioresorbable scaffolds.³⁴

Ostial lesions, Unprotected Left Main Disease, Chronic Total Occlusions and Stent Ablation

As described in the European expert consensus on rotational atherectomy,¹² there might still be angiographic settings where a more extensive ablation is desirable, i.e., ostial lesions, unprotected left main disease, chronic total occlusions and stent ablation. Ostial lesions, unprotected left main disease and chronic total occlusions have not been studied in a clinical trial with orbital atherectomy, but crossable lesions might be safely treated with a small crown size and adjustable ablation diameter with the rotational speed control. Stent ablation is contraindicated for orbital atherectomy. Whether orbital atherectomy would improve the outcomes of these lesion settings needs to be proved by future clinical studies.

Cost-effectiveness

Chamber et al. reported that the coronary OAS device offered a projected cost savings compared with the pooled population of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI)/Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials, as high as \$4,913 (€4,341), which was enough to offset the cost of the device, while still providing additional savings to the hospital.^{35,36} Specifically, reduced procedural complications, length of stay and readmission rate contribute to the cost-effectiveness. The economic study based on ORBIT II concluded that even in a low-value scenario, OAS offers a cost per life-year gained or incremental cost-effectiveness ratio of \$11,895 (€10,511). In the US, treatments are generally considered high value when they cost less than \$50,000 (€44,181) per life-year gained, and the OAS result was well below that threshold.

Figure 4: Typical Case Example of Angiography and Optical Coherence Tomography Images Pre- and Post-orbital Atherectomy

A patient presenting with stable angina was successfully treated by orbital atherectomy (1.25 mm classic crown) followed by drug-eluting stent implantation. Total orbital atherectomy system (OAS) run time was 93 seconds (two passes at 80,000 rpm and three passes at 120,000 rpm). Comparisons of pre-OAS OCT images (A–C) with corresponding post-OAS optical coherence tomography (OCT) images (A'–C') indicate the ablated areas by OAS (blue shadow).

Conclusion

The recent results of OAS trials appear to be encouraging; however, further trials in a randomised fashion are still required to conclude the true value of the OAS. The necessity for sufficient lesion preparation before implantation of bioresorbable scaffolds serves as important driving forces in performing a randomised study to compare the long-term outcomes of the two atherectomy devices and balloon angioplasty in patients with severely calcified lesions. ■

- Moussa I, Di Mario C, Moses J, et al. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results. *Circulation* 1997;**96**:128–36. PMID: 9236427
- Savage MP, Goldberg S, Hirshfeld JW, et al. Clinical and angiographic determinants of primary coronary angioplasty success. M-HEART Investigators. *J Am Coll Cardiol* 1991;**17**:22–8. PMID: 1987229
- Bourantas CV, Zhang YJ, Garg S, et al. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. *Heart* 2014;**100**:1158–64. DOI: 10.1136/heartjnl-2013-305180; PMID: 24846971
- Farooq V, Serruys PW, Bourantas CV, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation* 2013;**128**:141–51. DOI: 10.1161/CIRCULATIONAHA.113.001803; PMID: 23766350
- Abdel-Wahab M, Richardt G, Joachim Buttner H, et al. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial. *JACC Cardiovasc Interv* 2013;**6**:10–9. DOI: 10.1016/j.jcin.2012.07.017; PMID: 23266232
- de Waha S, Allali A, Buttner HJ, et al. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial. *Catheter Cardiovasc Interv* 2015; DOI: 10.1002/ccd.26290; PMID: 26525804; epub ahead of press
- Kobayashi Y, Teirstein P, Linnemeier T, et al. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. *Catheter Cardiovasc Interv* 2001;**52**:208–11. PMID: 11170330
- Brogan WC, 3rd, Popma JJ, Pichard AD, et al. Rotational coronary atherectomy after unsuccessful coronary balloon angioplasty. *Am J Cardiol* 1993;**71**:794–8. PMID: 8456756
- Authors/Task Force, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;**35**:2541–619. DOI: 10.1093/eurheartj/ehu278; PMID: 25173339
- Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;**58**:e44–122. DOI: 10.1161/CIR.0b013e31823ba622; PMID: 22064601
- Levine GN, O'Gara PT, Bates ER, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2016;**67**:1235–50. DOI: 10.1016/j.jacc.2015.10.005; PMID: 26498666
- Barbato E, Carrie D, Dardas P, et al. European expert consensus on rotational atherectomy. *EuroIntervention* 2015;**11**:30–6. DOI: 10.4244/EIJV11I1A6; PMID: 25982648

13. vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation* 2002;**105**:583–8. PMID: 11827923
14. Chambers JW, Feldman RL, Himmelstein SI, et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). *JACC Cardiovasc Interv* 2014;**7**:510–8. DOI: 10.1016/j.jcin.2014.01.158; PMID: 24852804
15. Adams GL, Khanna PK, Staniloae CS, et al. Optimal techniques with the Diamondback 360 degrees System achieve effective results for the treatment of peripheral arterial disease. *J Cardiovasc Transl Res* 2011;**4**:220–9. DOI: 10.1007/s12265-010-9255-x; PMID: 21312013
16. Madhavan MV, Tarigopula M, Mintz GS, et al. Coronary artery calcification: pathogenesis and prognostic implications. *J Am Coll Cardiol* 2014;**63**:1703–14. DOI: 10.1016/j.jacc.2014.01.017; PMID: 24530667
17. Tomey MJ, Kini AS, Sharma SK. Current status of rotational atherectomy. *JACC Cardiovasc Interv* 2014;**7**:345–53. DOI: 10.1016/j.jcin.2013.12.196; PMID: 24630879
18. Chambers JW, Diagne T. Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions. *Expert Rev Med Devices* 2014;**11**:457–66. PMID: 24961517
19. Kini A, Marmur JD, Duvvuri S, et al. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1,000 patients. *Catheter Cardiovasc Interv* 1999;**46**:305–11. PMID: 10348127
20. Sotomi Y, Shammam NW, Suwannasom P, et al. Impact of the Orbital Atherectomy System on a Peripheral Calcified Lesion: Quantitative Analysis by Intravascular Echogenicity. *JACC Cardiovasc Interv* 2015;**8**:e205–6. DOI: 10.1016/j.jcin.2015.06.021; PMID: 26386765
21. Sotomi Y, Shlofmitz RA, Nakatani S, et al. Impact of the orbital atherectomy system on a coronary calcified lesion: quantitative analysis by light attenuation in optical coherence tomography. *Eurointervention* 2015;**11**:e1. DOI: 10.4244/EIJV11I5A110; PMID: 26390508
22. Parikh K, Chandra P, Choksi N, et al. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. *Catheter Cardiovasc Interv* 2013;**81**:1134–9. DOI: 10.1002/ccd.24700; PMID: 23460596
23. Bhatt P, Parikh P, Patel A, et al. Orbital atherectomy system in treating calcified coronary lesions: 3-Year follow-up in first human use study (ORBIT I trial). *Cardiovasc Revasc Med* 2014;**15**:204–8. DOI: 10.1016/j.carrev.2014.03.004; PMID: 24746600
24. Bhatt P, Parikh P, Patel A, et al. Long-term safety and performance of the orbital atherectomy system for treating calcified coronary artery lesions: 5-Year follow-up in the ORBIT I trial. *Cardiovasc Revasc Med* 2015;**16**:213–6. DOI: 10.1016/j.carrev.2015.03.007; PMID: 25866032
25. Matsuo H, Watanabe S, Watanabe T, et al. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy—a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. *Am Heart J* 2007;**154**:994.e1–6. PMID: 17967610
26. Kume T, Okura H, Kawamoto T, et al. Assessment of the histological characteristics of coronary arterial plaque with severe calcification. *Circ J* 2007;**71**:643–7. PMID: 17456985
27. Reisman M, Harms V, Whitlow P, et al. Comparison of early and recent results with rotational atherectomy. *J Am Coll Cardiol* 1997;**29**:353–7. PMID: 9014988
28. Rathore S, Matsuo H, Terashima M, et al. Rotational atherectomy for fibro-calcific coronary artery disease in drug eluting stent era: procedural outcomes and angiographic follow-up results. *Catheter Cardiovasc Interv* 2010;**75**:919–27. DOI: 10.1002/ccd.22437; PMID: 20432398
29. Mauri L, Reisman M, Buchbinder M, et al. Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). *Am Heart J* 2003;**145**:847–54. PMID: 12766743
30. Furuichi S, Tobaru T, Asano R, et al. Rotational atherectomy followed by cutting-balloon plaque modification for drug-eluting stent implantation in calcified coronary lesions. *The Journal of invasive cardiology* 2012;**24**:191–5.
31. Kini AS, Vengrenyuk Y, Pena J, et al. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. *Catheter Cardiovasc Interv* 2015;**86**:1024–32. DOI: 10.1002/ccd.26000; PMID: 25964009
32. Bangalore S, Vlachos HA, Selzer F, et al. Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. *Catheter Cardiovasc Interv* 2011;**77**:22–8. DOI: 10.1002/ccd.22613; PMID: 20506328
33. Foley DP, Pieper M, Wijns W, et al. The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions; final results of the Magic 5L Study. *Eur Heart J* 2001;**22**:1585–93. PMID: 11492988
34. Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. *JACC Cardiovasc Interv* 2014;**7**:741–50.
35. Chambers J, Genereux P, Lee A, Lewin J, Young C, Crittendon J, Mann M and Garrison LP. The potential cost-effectiveness of the Diamondback 360(R) Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach. *Therapeutic advances in cardiovascular disease* 2015; PMID: 26702147; epub ahead of press.
36. Genereux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *J Am Coll Cardiol* 2014;**63**:1845–54. DOI: 10.1016/j.jacc.2014.01.034; PMID: 24561145
37. Instructions for use "DIAMONDBACK 360® Coronary Orbital Atherectomy System" 2015.
38. Shlofmitz E, Chambers J, Moses JW, Martinsen B, Meraj P, Jauhar R and Shlofmitz R. Temporary Pacemaker Placement Incidence with the Diamondback 360 Coronary Orbital Atherectomy System Compared to Rotational Atherectomy. *J Am Coll Cardiol* 2015;**66**:SUPPL B. DOI:10.1016/j.jacc.2015.08.1005
39. Genereux P, Lee AC, Kim CY, et al. Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial). *Am J Cardiol* 2015;**115**:1685–90. DOI: 10.1016/j.amjcard.2015.03.009; PMID: 25910525
40. Ruisi M, Zachariah J, Ratcliffe J, Lala M, Ruisi P, Huang Y, Diwan R, Daggubati R, Patel T and Kwan TW. Safety and Feasibility of the Coronary Orbital Atherectomy System via the Transradial Approach. *J Invasive Cardiol* 2015;**27**:E252–5. PMID: 26524211
41. Dib N. Coronary flow reserve following orbital atherectomy and percutaneous revascularization in severely calcified coronary lesions. Available at: <https://www.clinicaltrials.gov/ct2/show/NCT02339545> (accessed 20 March 2016).
42. Stone G. Coronary Orbital Atherectomy System Study (COAST) Available at: <https://clinicaltrials.gov/ct2/show/NCT02132611> (accessed 20 March 2016).